FDA posts Provenge documents

Data submitted by Dendreon (DNDN) on Provenge sipuleucel-T "tend to support a finding of clinically meaningful increased survival, but doubts remain about the persuasiveness of the efficacy data,"

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE